Generics versus Big Pharma

Yet over the past decade in particular, most of the Big Pharma’s have adopted small molecule generics in one shape or form into their overall business model. And many of them openly talk about the “innovation headroom” that a healthy low-priced generics market enables i.e. the money saved on off-patent drugs can be used to fund high-priced new innovations. They have recognized that they cannot fight the realities of aging populations and healthcare economics.


    Related Conference of Generics versus Big Pharma

    April 04-05, 2024

    17th European Biosimilars Congress

    Madrid, Spain
    April 11-12, 2024

    5th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 09-10, 2024

    4th Global Summit on Pharmaceutical Research

    Barcelona, Spain
    May 16-17, 2024

    18th World Drug Delivery Summit

    Rome, Italy
    May 30-31, 2024

    9th Pharmaceutical Chemistry Conference

    Paris, France
    July 25-26, 2024

    34th Annual European Pharma Congress

    Frankfurt, Germany
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2024

    3rd World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2024

    3rd World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 28-29, 2024

    39th World Congress on Pharmacology and Therapeutics

    Paris, France
    November 28-29, 2024

    12th International Conference on Clinical Trials

    Vancouver, Canada
    December 05-06, 2024

    17th World Drug Delivery Summit

    Dubai, UAE

    Generics versus Big Pharma Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in